Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
- Conditions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 254
- Registration Number
- NCT05683977
- Locations
- 🇫🇷
Research Site, Évreux, France
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
- Conditions
- Interventions
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2023-01-05
- Target Recruit Count
- 70
- Registration Number
- NCT05672537
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT05655949
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2022-12-07
- Target Recruit Count
- 40
- Registration Number
- NCT05640791
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT05632809
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
- Conditions
- Interventions
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1075
- Registration Number
- NCT05629585
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer
- Conditions
- Interventions
- Drug: CarboplatinDrug: CisplatinProcedure: Computed TomographyBiological: DurvalumabDrug: EtoposideRadiation: Image Guided Radiation TherapyDrug: PaclitaxelDrug: PemetrexedProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 474
- Registration Number
- NCT05624996
- Locations
- 🇺🇸
UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
🇺🇸Ascension Borgess Hospital, Kalamazoo, Michigan, United States
🇺🇸Benefis Sletten Cancer Institute, Great Falls, Montana, United States
Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)
- Conditions
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Jeeyun Lee
- Target Recruit Count
- 25
- Registration Number
- NCT05620628
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 550
- Registration Number
- NCT05617963
- Locations
- 🇫🇷
Institut du Cancer Avignon-Provence, Avignon, France
🇫🇷Centre d'Oncologie du Pays Basque, Bayonne, France
🇫🇷CH de la côte Basque, Bayonne, France
Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2023-09-28
- Target Recruit Count
- 37
- Registration Number
- NCT05582538
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori IRCCS, Milano, Italy
🇮🇹Istituto Oncologico Veneto IRCCS, Padova, Italy
🇮🇹Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.